Synairgen Share Discussion Threads

[makendon] 17/4/2020 07:51

Apologies if posted before;





First MFT patient recruited to Synairgen COVID-19 research trial
Posted: Thursday Apr 16th 2020
Our first patient has taken part in a research trial testing whether SNG001 – a drug treatment administered via a nebuliser – could be a potential treatment for COVID-19 (coronavirus).

The first Manchester University NHS Foundation Trust (MFT) patient was recruited at Wythenshawe Hospital this week, as part of a multidisciplinary team effort to tackle the virus.

The trial is taking place at hospitals across the UK, with our Trust a participating site. The research is sponsored by Synairgen Research Limited, a respiratory drug discovery and development company founded by the University of Southampton, which focusses primarily on lung viral defence in asthma and COPD.

SNG001 is an inhaled formulation of interferon-beta-1a (IFN-β1a), a respiratory drug which has been found to inhibit viruses and boost antiviral responses in the lungs. It has already been used in clinical trials of patients with asthma and COPD. These earlier trials indicated that SNG001 was well tolerated during virus infections and provided significant lung function benefit for asthma patients, compared to a placebo.

There are currently no approved treatments for COVID-19, but researchers believe SNG001 could help prevent the worsening, or accelerate the recovery of patients with severe lower respiratory tract illness, brought on by COVID-19.

There are currently five other COVID-19 research trials open at MFT, with more in set-up, due to open imminently.

Dr Tim Felton, Honorary Consultant in Intensive Care and Respiratory Medicine at Wythenshawe Hospital and our Clinical Lead for MFT COIVID-19-related studies, said: “As of 16 April, more than 1,000 patients have been recruited to COVID-19 trials at MFT and that number is growing every day.

“Our research spans four workstreams – data, diagnostics, observational and treatments – with this SNG001 study being one of our ‘treatments’ trials, which are looking at different medications we can use to treat patients with COVID-19.

“We carry out research when we don’t know the answers, but if SNG001 proves to be beneficial it would be a major breakthrough for the treatment of COVID-19.”

[markinvestor] 17/4/2020 07:47

DOW futures +727, FTSE +122 with Asia strong overnight...hopefully a day of Green/Blue

[pdt] 17/4/2020 07:32

Interesting that Gilead's antiviral Remdesivir is potentially having some success. Gilead's stock price increased 15% after hours suggesting an increase in market cap of over £10 billion. That is on top of the billion dollar gains already seen.

Assuming it is approved it will set a price benchmark for SNG to follow all being well. And also establish an approval process.

It goes to show that SNG's market cap of £80 million is hardly expensive. IMHO.

Hopefully, SNG recruitment will complete in the next few days. If at least 5 sites are up and running they are recruiting perhaps 10 people per day?

[nobbygnome] 17/4/2020 07:26

$15 billion....and SNG in total is valued at about £90 million! Plus SGN001 is in a placebo controlled trial so will produce a statistically relevant result.

The value here is clear....

[oapknob1] 17/4/2020 07:19

Hope they get a cure quickly- worth a read Gilead Shares Jump 15% After-Market on Positive But Inconclusive ReportSource: Dow Jones News By Joseph WalkerInteresting final paragraphs in the article-Analysts cautioned that the severe-patient study doesn't include a comparison group, making it difficult to interpret the results, and that the drug is unlikely to be a significant financial driver for Gilead."While a potential treatment for patients with severe COVID is encouraging, the market cap increase in GILD on this news ($15B) appears inconsistent with the potential financial value to Gilead in our view," Morgan Stanley said in a note to clients.

[nobbygnome] 17/4/2020 06:59

I am an amateur chartist and think his 85p target is very reachable. However, his trend line which might suggest 120p is extremely tenuous IMHO.....

[lauders] 17/4/2020 06:54

For the chartists (I am not one) SNG is mentioned here from 5.50 minutes/seconds in:

[hazl] 17/4/2020 06:41

THANKS to gwr7 for general info.

[markinvestor] 17/4/2020 06:34

Just some Pharma news overnight...

Gilead Sciences Inc’s shares surged 16% in after hours trading on Thursday following a media report detailing encouraging partial data from trials of the US company’s experimental drug remdesivir in severe Covid-19 patients.

A University of Chicago hospital participating in a study of the antiviral medication said it is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week

[potts650] 17/4/2020 01:49

Interesting reading on Inferon type 1, including beta-1a

[peachie 74] 16/4/2020 23:21

It seems by far the most promising treatment line as far as I can see through my research. Definitely the safest.

The beauty of it is it’s prophylactic and future potential. It’s not just all about Covid 19. But if effective against it then these prices in pence will seem ludicrous.
IMHO
DYOR. I have

[nobbygnome] 16/4/2020 22:22

There really is so much evidence that interferon works when given by inhalation. It all bodes very well....

[peachie 74] 16/4/2020 21:47

Very good spot !

[crookie3634] 16/4/2020 21:28

Good spot how many, explains it perfectly:)

[likya123] 16/4/2020 21:27

From lse board...

I do not know how respectable the source is btw but thought i would share) 

'Gerardo Guillen, director of the Biomedical Researches at the Center for Genetic Engineering and Biotechnology (CIGB), reported that the molecule's nebulization use is a rapid way to reach the airway being able to act in early stages of infection; thus, Cuba will have a variant ready for nasal use this week that will initially be applied to health personnel for their protection.'

[howmanyfools] 16/4/2020 21:20

Synairgen RNS Thursday 26th March:

"In addition, Lansdowne Partners Ltd ("Lansdowne") is a substantial shareholder in the Company holding 10 per cent. or more of the existing issued Ordinary Shares and has agreed to subscribe for 4,285,714 Placing Shares at the Issue Price, representing 10.7 per cent. of the total New Ordinary Shares."

[crookie3634] 16/4/2020 20:52

Does anyone commit 4 million on the placement without having asked the CEO what the actual potential of this drug working is? I can’t see it they would have asked and be confident enough on the response that it does what they hope. Holding that many shares gives you privy knowledge.

[crookie3634] 16/4/2020 20:48

It’s not directly but work out 18% of 120 mil which was previous holding and then work out 16.7% of 149 mil and you will see it is an increase. Looks on face value as a decrease or simple placement % adjustment but it’s not it is an increase in shares. What we don’t know is how many did they have ie did they sell 4 mill and keep 4 mill and announce as one. Who took the other 36 mil we know the Directors has a few and Link didn’t another TR1 to come? I think it could explain some of the trading pattern drop the price fill the order and then rise and repeat.

[talk2dubya] 16/4/2020 20:46

Would love it if true !

[l2e] 16/4/2020 20:43

Bristol Myers

[oapknob1] 16/4/2020 20:37

Where is the increase shown?

[crookie3634] 16/4/2020 20:29

OAP do you think they had more and then sold off some and announced as one today?

[crookie3634] 16/4/2020 20:27

It is an increase in their holding of shares, I would guess this is there contribution to the recent placing? Who took the other 36 million?